Drug-induced parkinsonism

被引:36
作者
Susatia, Frandy [1 ]
Fernandez, Hubert H. [1 ]
机构
[1] McKnight Brain Inst, Gainesville, FL 32610 USA
关键词
MOVEMENT-DISORDERS; RATING-SCALE; EXTRAPYRAMIDAL SYNDROMES; RECEPTOR OCCUPANCY; INDUCED PSYCHOSIS; DOUBLE-BLIND; DISEASE; CLOZAPINE; ANTIPSYCHOTICS; DOPAMINE;
D O I
10.1007/s11940-009-0019-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Drug-induced parkinsonism (DIP) is condition that mimics Parkinson's disease. Characterized mainly by rigidity and bradykinesia, it has less prominent tremor and gait instability. DIP is generally caused by lipophilic drugs that "block" dopamine D2 receptors in the brain, although presynaptic dopamine depletion, false transmitters, mitochondrial respiratory chain dysfunction, and overactivity in the gamma-aminobutyric acid (GABA)ergic system or cholinomimetic action have also been postulated as possible mechanisms. The onset of DIP is acute to subacute. It is more common in women and has a bimodal age distribution. Other diseases that can resemble DIP include neuropsychiatric conditions (eg, depression, negative symptoms of schizophrenia) and Wilson's disease. Physicians may be able to prevent DIP by prescribing neuroleptic agents appropriately and with caution. The risk of DIP is presumably lower with the use of "atypical" antipsychotic agents but it is not eliminated, especially in those most vulnerable to parkinsonism (eg, the elderly or cognitively impaired). The best treatment is discontinuation of the provoking medication. Prospective studies are needed to further define the mechanism of DIP, identify individual susceptibility, determine the impact of atypical antipsychotic agents, and develop further treatment options for those unable to stop the offending agent.
引用
收藏
页码:162 / 169
页数:8
相关论文
共 62 条
[31]   Management of acute extrapyramidal effects induced by antipsychotic drugs [J].
Holloman, LC ;
Marder, SR .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (21) :2461-2477
[32]  
Hornykiewicz O, 1975, Adv Neurol, V9, P155
[33]   Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol [J].
Inada, T ;
Beasley, CM ;
Tanaka, Y ;
Walker, DJ .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (01) :39-48
[34]  
ING TS, 1979, CAN MED ASSOC J, V120, P695
[35]  
JANSEN ENH, 1994, ACTA NEUROL SCAND, V89, P262
[36]   Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action [J].
Kapur, S ;
McClelland, RA ;
VanderSpek, SC ;
Wadenberg, MLG ;
Baker, G ;
Nobrega, J ;
Zipursky, RB ;
Seeman, P .
NEUROREPORT, 2002, 13 (06) :831-835
[37]  
KEEPERS GA, 1983, ARCH GEN PSYCHIAT, V40, P1113
[38]   Metric characteristics of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS): A practical combined rating scale for drug-induced movement disorders [J].
Kim, JH ;
Jung, HY ;
Kang, UG ;
Jeong, SH ;
Ahn, YM ;
Byun, HJ ;
Ha, KS ;
Kim, YS .
MOVEMENT DISORDERS, 2002, 17 (06) :1354-1359
[39]   Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol [J].
Lieberman, JA ;
Tollefson, G ;
Tohen, M ;
Green, AI ;
Gur, RE ;
Kahn, R ;
McEvoy, J ;
Perkins, D ;
Sharma, T ;
Zipursky, R ;
Wei, H ;
Hamer, RM .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (08) :1396-1404
[40]  
Loonen AJM, 2001, INT J NEUROPSYCHOPH, V4, P347, DOI 10.1017/S1461145701002589